Human Endothelial-Cell Specific Molecule-1 Binds Directly to the Integrin CD11a/CD18 (LFA-1) and Blocks Binding to Intercellular Adhesion Molecule-1

David Béchard, Arnaud Scherpereel, Hamida Hammad, Thibaut Gentina, Anne Tsicopoulos, Marc Aumercier, Joël Pestel, Jean-Paul Dessaint, André-Bernard Tonnel and Philippe Lassalle

*J Immunol* 2001; 167:3099-3106; doi: 10.4049/jimmunol.167.6.3099
http://www.jimmunol.org/content/167/6/3099
Human Endothelial-Cell Specific Molecule-1 Binds Directly to the Integrin CD11a/CD18 (LFA-1) and Blocks Binding to Intercellular Adhesion Molecule-1

David Béchard,† Arnaud Scherpereel,‡ Hamida Hammad,∗ Thibaut Gentina,∗ Anne Tsicopoulos,* Marc Aumercier,† Joël Pestel,* Jean-Paul Dessaint,‡ André-Bernard Tonnel,* and Philippe Lassalle2*

ICAMs are ligands for LFA-1, a major integrin of mononuclear cells involved in the immune and inflammatory processes. We previously showed that endothelial cell specific molecule-1 (ESM-1) is a proteoglycan secreted by endothelial cells under the control of inflammatory cytokines. Here, we demonstrate that ESM-1 binds directly to LFA-1 onto the cell surface of human blood lymphocytes, monocytes, and Jurkat cells. The binding of ESM-1 was equally dependent on Ca2+, Mg2+, or Mn2+ divalent ions, which are specific, saturable, and sensitive to temperature. An anti-CD11a mAb or PMA induced a transient increase in binding, peaking 5 min after activation. Direct binding of ESM-1 to LFA-1 integrin was demonstrated by specific coinmunoprecipitation by CD11a and CD18 mAbs. A cell-free system using a Biacore biosensor confirmed that ESM-1 and LFA-1 dynamically interacted in real time with high affinity (Kd = 18.7 nM). ESM-1 consistently inhibited the specific binding of soluble ICAM-1 to Jurkat cells in a dose-dependent manner. These results suggest that ESM-1 and ICAM-1 interact with LFA-1 on binding sites very close to but distinct from the I domain of CD11a. Through this mechanism, ESM-1 could be implicated in the regulation of the LFA-1/ICAM-1 pathway and may therefore influence both the recruitment of circulating lymphocytes to inflammatory sites and LFA-1-dependent leukocyte adhesion and activation. The Journal of Immunoology, 2001, 167: 3099–3106.
regulation of its expression by proinflammatory cytokines, prompted us to examine the possibility that ESM-1 could affect the behavior of mononuclear cells. In the present work, we demonstrate that purified ESM-1 binds to human PBL and monocytes. Binding studies on several human leukocytic cell lines indicate that ESM-1 bound to a specific cell surface molecule on Jurkat cells. Coimmunoprecipitation and Bioconjugate analysis identified the β3 integrin LFA-1 as the specific receptor of ESM-1, and ESM-1 was shown to inhibit the binding of soluble ICAM-1 to Jurkat cells. Therefore, ESM-1 is an extracellular ligand for LFA-1 and may be considered as a soluble immunomodulator of the LFA-1/ICAM-1 pathway.

Materials and Methods

Reagents, cell lines, and cell culture

Anti-CD11a (clone HI111 (blocking) and clone G43-25B (nonblocking)), anti-CD11b (clone ICRF44), anti-CD18 (clone 6.7), anti-CD2, and anti-CD3 mAbs were purchased from BD Pharmingen (San Diego, CA). Anti-CD44 mAb was purchased from Sigma-Aldrich (St. Louis, MO). CM5 Sensor Chips were obtained from Biacore (Uppsala, Sweden). The development of HEK293 cell lines expressing the wild type of ESM-1 (ESM/WT) has been previously described.3 ESM/WT was produced by an established cell line called 293-ESM. ESM/WT from conditioned cell supernatants was purified sequentially by ion exchange chromato graphy (DEAE-Sepharose) followed by immunofluorimetry chromatography with mouse mAb to ESM-1 produced by Chinese hamster ovary cells (MEC)-4 mAb. Azogazo column (Bio-Rad, Hercules, CA) (see Production of anti-ESM-1 mAbs below). The bound material was then eluted in 3 M MgCl2, concentrated, dialyzed, and stored at −70°C. The protein level was evaluated by Bio-Rad assay Coomassie blue- or Acanth blue-stained SDS-PAGE. The ESM-1 level was assessed by ELISA. The level of ESM-1 cDNA was checked by a Limulus amebocyte lysate assay. Aliquots of 200 ng/ml ESM-1 in PBS containing 0.1% BSA were kept frozen at −70°C and served for the standard curve ranging from 0.1 to 10 ng/ml. The lymphoblastic cell line Jurkat and SIB-1, monocytic cell line U937, and myelocytic cell line HL60 were cultured in RPMI 1640 medium with 10% FCS and 2 mM l-glutamine. The monotypic cell line THP1 was cultured in DMEM, 10% FCS, and 2 mM l-glutamine. Transfected and established cell lines producing soluble ESM-1 and soluble ICAM-1 (293-ESM and 293-3D-ICAM-1/Fc) were cultured in DMEM 10% FCS, and 2 mM l-glutamine. PBMC were obtained from healthy individual volunteers after Ficoll gradient centrifugation (Pharmacia Biotech, Uppsala, Sweden). Mononuclear cells were resuspended in RPMI 1640 supplemented with 10% FCS, 2 mM l-glutamine, and antibiotics.

Production of anti-ESM-1 mAbs

To obtain anti-ESM-1 mAbs against the cysteine-rich region of ESM-1, the native form of ESM-1 was purified from an established Chinese hamster ovary-ESM cell line. BALB/C mice were immunized (10 μg/mouse) with a standard immunization protocol using CFA. Hybridoma cells secreting anti-ESM-1 mAbs were obtained by fusion, screening, and subcloning as previously described.20) Five hybridoma cell clones were obtained and were called MEC. Four of them were of IgG1, isotype (MEC 4.5, 15, and 36), and one of them was of IgM, k isotype (MEC 11). The hybridoma clones were cultured in serum-free medium, and anti-ESM-1 mAbs were purified on protein G-Sepharose chromatography (Pharmacia Biotech).

Flow cytometric analysis

Binding of ESM-1 to PBMC and Jurkat cells was analyzed by a FACs-calibur (BD Biosciences, San Jose, CA). A total of 500,000 cells were incubated with 200 μl of 300 ng/ml purified ESM-1 in incubating buffer containing PBS, 1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, and in some experiments, 5 mM EDTA for 1 h at 4°C. Cells were washed three times in buffer and incubated with an anti-ESM-1 mAb, MEC 15, vs an isotype-matched mouse IgG1 as a negative control for 30 min at 4°C. After washing, cells were incubated with a FITC-anti-mouse IgG at 1:100 and washed three times before FACS analysis. Mean fluorescence ratio (MFR) was calculated by dividing mean fluorescence intensity (MFI) of the sample by the MFI of the control; thus, a MFR of 1 is equivalent to background.

Quantitative binding evaluation

To evaluate the binding of ESM-1 to different leukocytic cell lines, ~1 × 106 cells (Jurkat, SIB-1, THP1, U937, and HL60) were incubated in 2 ml RPMI 1640 medium containing 300 ng/ml purified ESM-1 for 1 h at 4°C. Cells were centrifuged at 1500 rpm for 5 min at 4°C, washed three times in ice-cold buffer without ESM-1, and lysed at 4°C in 500 μl of lysis buffer containing PBS, complete anti-proteases mixture with EDTA (Boehringer Mannheim, Mannheim, Germany), and 0.5% Nonidet P-40 (Boehringer Mannheim). After removal of insoluble material by centrifugation at 10,000 rpm for 15 min, bound ESM-1 was quantified by a specific ELISA.20) In some experiments, the binding of ESM-1 to Jurkat cells was performed at 37°C. The cell suspension, preheated to 37°C, was activated with PMA (100 ng/ml) for various periods of time from 5 to 30 min. The tubes were then cooled on ice, incubated with ESM-1 for 1 h at 4°C, and then washed with ice-cold incubating medium. To evaluate the divalent ion dependence of the binding, Jurkat cells were incubated in PBS containing either 1 mM CaCl2, 1 mM MgCl2, or 1 mM MnCl2 in the presence of 300 ng/ml purified ESM-1 for 1 h at 4°C. Jurkat cells were also incubated in RPMI 1640 medium containing 300 ng/ml purified ESM-1, with or without 5 mM EDTA, for 1 h at 4°C.

Coimmunoprecipitation procedure

Approximately 5 × 106 Jurkat cells were incubated in 10 ml of RPMI 1640 complemented with purified ESM-1 at a concentration of 300 ng/ml with MgCl2, MnCl2, and CaCl2 at 1 mM each for 1 h at 4°C. Then cells were washed three times in ice-cold RPMI 1640 medium and were lysed in 500 μl of a specific lysis buffer (PBS and EDTA-free complete anti-protease mixture, 1 mM MgCl2, 1 mM MnCl2, 1 mM CaCl2, and 5 mM octylthio-glucoside (Boehringer Mannheim) for 30 min at 4°C. After removal of insoluble material by centrifugation at 10,000 rpm at 4°C, supernatants were incubated with 6 μg of different mouse mAbs at 4°C. After 2 h, 150 μl of anti-mouse Fc agarose beads were added during 1 h at 4°C. Then beads were washed three times in lysis buffer by centrifugation at 2500 rpm at 4°C. Next, beads were eluted with 200 μl of 3 M MgCl2 for 10 min at room temperature. After rapid centrifugation, 200 μl of eluate was resuspended with 3 ml of PBS containing 1 tablet of complete anti-proteases mixture. Eluate was desalted and was concentrated on 30-kDa Amicon (Amicon, Beverly, MA). ESM-1 was quantified by using a specific ELISA.

The cell membrane-associated molecules from Jurkat cells were considered conserved in their functional status based on the optimization of the solubilization procedure. In particular, the solubilized LFA-1 molecule was verified to be heterodimeric by Biacore and differential immunoprecipitation immunoblot procedures (data not shown).

Real-time bimolecular interaction assay

The Biacore system was used. In this system, binding of soluble ligands to immobilized ligands was measured in arbitrary units (resonance units, RU). There was a linear relationship between the mass of the protein bound to the immobilized protein and the RU observed (1000 RU = 1 ng/mm2 bound protein). An anti-CD11a (HI111) mouse mAb was immobilized at 8000 RU to the carboxymethylated dextrin matrix of the sensor chip according to the manufacturer’s protocol using the Amine Coupling Kit (Bia-core). A control mixture was compared with control surface (sham blocked sensor surface). LFA-1 molecules from the Jurkat lysates could only be fixed by immunofluorimetry procedure. Approximately 2 × 106 Jurkat cells were lysed in 2 ml of lysis buffer (PBS, 1 mM MgCl2, 1 mM MnCl2, complete anti-protease mixture (EDTA-free), and 5 mM octylthioglucoside) for 30 min at 4°C. After removal of insoluble material by centrifugation and incubation in a sonication bath, the lysate was injected at a flow rate of 5 μl/min for 30 min at 25°C to immobilize approximately 1500 RU LFA-1 molecules. Next, CD11a mAb (G43-25B), CD18 mAb, and purified ESM-1 were diluted in running buffer (PBS, 1 mM MgCl2, and 1 mM MnCl2) and injected at a flow rate of 5 μl/min for 5 min at 25°C. The Kd and Kd were calculated according to the BIAevaluation software version 3.1 provided by the manufacturer. The affinity constant was calculated from the equation Kd = Kd/Kd.
Jurkat cells before 3D-ICAM-1/Fc binding.

optimal effect of ESM-1, some experiments were conducted with increas-

Analysis of the binding of soluble ICAM-1/Fc to Jurkat cells

Jurkat cells were incubated in RPMI 1640 medium supplemented or not with ESM-1 at a concentration of 300 ng/ml for 1 h at 4°C. Cells were washed twice in RPMI 1640 medium and incubated in medium supplemented with radiolabeled soluble 3D-ICAM-1/Fc (1 μg/ml) for 30 min either at 4°C or at 37°C. Cells were washed twice with medium heated at corresponding temperatures and resuspended in 2 ml of scintillation liquid. Binding of soluble 3D-ICAM-1/Fc was evaluated by cpm counting in a Beckman counter (Beckman, Rouissy, CDG, France). To determine the optimal effect of ESM-1, some experiments were conducted with increasing concentrations of ESM-1 ranging from 1 to 1000 ng/ml incubated with Jurkat cells before 3D-ICAM-1/Fc binding.

Results

ESM-1 binds to the surface of PBMC and Jurkat cells

To study the possibility that ESM-1 may interact with PBMC obtained from healthy volunteers, we explored the binding ability of ESM-1 to PBMC by flow cytometric analysis. When human PBMC were incubated with ESM-1, a consistent and specific binding to the cell surface of human lymphocytes (MFI = 12.07 ± 2.3; MFR = 2.9) was observed as compared with the cells not incubated with ESM-1 (MFI = 4.12 ± 0.9). In addition, human monocytes also bound ESM/WT (MFI = 25.59 ± 3.6; MFR = 1.7) as compared with control monocytes (MFI = 14.78 ± 1.3) (Fig. 1).

To better characterize the cell surface binding of ESM-1, several cell lines (Jurkat and SIB-1 lymphoblastoid, U937 and THP1 monocytoid, and HL60 myeloid cell lines) were examined for their ability to bind ESM-1. As shown in Fig. 1, ESM-1 bound to the cell surface of Jurkat cells (MFI = 7.51 ± 0.8; MFR = 3.4) as compared with Jurkat cells not incubated with ESM-1 (MFI = 2.22 ± 0.5). SIB-1 cells, a B lymphoblastoid cell line, also bound ESM-1 to a similar extent as Jurkat cells. In contrast, U937, THP1, and HL60 cells did not show any significant ESM-1 binding (data not shown). To quantify the presence of ESM-1 on the cell surface, bound ESM-1 was released by complete cell lysis and was evaluated by a specific ELISA. In a resting state, only Jurkat and SIB-1 lymphoblastoid cell lines were able to bind constitutively and significantly to ESM-1 (Fig. 2). The results are in agreement with the MFR, suggesting that ESM-1 in cell lysates reflected the cell surface-bound ESM-1. It is unlikely that the ESM-1 level in cell lysates was related to an endocytic form of ESM-1 because all the experiments were performed on ice, and monocytoïd cell lines were negative. In contrast, no ESM-1 or related forms were detected by RT-PCR and specific ELISA, discarding any endogenous synthesis and expression of ESM-1, but suggesting the presence of a specific receptor for ESM-1 on their surface.

Binding of ESM-1 on Jurkat cells is divalent ion-dependent and saturable

The binding of ESM-1 to Jurkat cells was completely abolished by the presence of EDTA in the medium (Figs. 1 and 3A). Incubation of Jurkat cells with purified ESM-1 in PBS alone did not lead ESM-1 to bind. In contrast, the single addition of either Ca2+, Mg2+, or Mn2+ ions in PBS medium was able to restore the binding of ESM-1 to Jurkat cells in a similar fashion for each of the three divalent ions (Fig. 3B). Dose-response curves of bound ESM-1 were titrated in the presence or absence of EDTA. The amount of bound ESM-1 that was divalent ion dependent was obtained after subtraction of the amount of ESM-1 bound. The resulting curve demonstrated that bound ESM-1 reached a plateau beginning at 4 nM (Fig. 3C). Experiments conducted with 2 × 107 and 5 × 107 cells/point gave curves with a similar plateau. These results point to the presence of a divalent ion-dependent and saturable binding site for ESM-1 on the surface of Jurkat cells.

FIGURE 1. ESM-1 binds specifically to the cell surface of human lymphocytes, monocytes, and Jurkat cells. Lymphocytes, monocytes, and Jurkat cells bound consistently and specifically ESM/WT, and this binding activity disappeared in the presence of EDTA. PBMC and Jurkat cells were incubated either in the presence of purified ESM/WT (2), EDTA (5 mM) plus ESM/WT (3), or buffer alone (1) for 1 h at 4°C. Bound ESM-1 was detected by a specific MEC15 mAb (clear line) vs an isotype-matched IgG1 as negative control (bold line) followed by a FITC-conjugated anti-

FIGURE 2. Analysis of the binding of ESM-1 to different leukocytic cell lines. ESM-1 specifically binds to the lymphoblastoid cell lines. Binding studies of ESM-1 were performed on lymphoblastoid cell lines (Jurkat and SIB-1), monocytoïd cell lines (THP1 and U937), and a myeloid cell line (HL60), each in resting state. Cells were incubated in the presence of ESM/WT for 1 h at 4°C, and detection of their bound ESM-1 was quantified in cell lysates by a specific ELISA. Data (n = 5) are expressed in nanograms per milliliter ESM-1 from a 500-μl total volume of cell lysate.
Role of temperature and PMA activation

The effect of temperature on ESM-1 binding to Jurkat cells was also evaluated. The binding of ESM-1 at 37°C still persisted but to a lesser extent than at 4°C (Fig. 4A). Identical results were obtained with two different cell concentrations. Nearly half the quantity of bound ESM-1 was lost by shifting the binding temperature to 4°C. Binding experiments with D–[6-3H]glucosamine-labeled ESM-1 gave a similar result: a reduced level of bound radioactivity at 37°C (51 cpm) compared with that detected at 4°C (370 cpm, data not shown). These results suggest that membrane fluidity, metabolic energy, or internalization are involved in the dissociation of bound ESM-1 from Jurkat cells. To appreciate a possible modulation of ESM-1-binding activity, Jurkat cells were activated nonspecifically by PMA. Kinetics of activation showed a rapid increase at 5 min of incubation with PMA (Fig. 4B), with a transient increase in ESM-1 binding (17.2 ± 10 ng/10^6 Jurkat cells) (Fig. 5A). However, anti-CD11a mAbs were differentially able to coimmunoprecipitate bound ESM-1; the blocking anti-CD11a mAb (clone HI111), which is known to inhibit the binding of ICAM-1, coimmunoprecipitated ESM-1, whereas the nonblocking anti-CD11a mAb (clone G43-25B) was inefficient, despite similar MFIs obtained by FACS. To test whether anti-CD11a mAbs could modify the binding of ESM-1 to Jurkat cells, Jurkat cells were incubated first with different mAbs and then subjected to ESM-1-binding analysis. Surprisingly, as shown in Fig. 5B, the anti-CD11a mAb (clone HI111), in the presence of divalent ions, led to a consistent increase in ESM-1 binding (17.2 ± 1.5 ng/ml), as compared with controls in absence of specific mAb (5.8 ± 0.3 ng/ml) and with the

normalization of the ESM-1 binding after 15 min of activation, arguing for the presence at the surface of Jurkat cells of a regulated binding site for ESM-1.

Anti-LFA-1 mAb coimmunoprecipitates ESM-1 and LFA-1 and enhances the binding of ESM-1 to Jurkat cells

To identify the binding site of ESM-1, we focused on the β2 integrins because of some amino acid sequence homologies between ESM-1 and the cysteine-rich region of CD18 (19). This led us to speculate that ESM-1 might bind to the α-chain of β2 integrins, the most interesting candidates because they are expressed on both PBMC and Jurkat cells. ESM-1 was reproducibly coimmunoprecipitated from Jurkat cells by the anti-ESM-1 mAb clone MEC15 (positive control) (14.1 ± 3.2 ng/ml) and, interestingly, also by the anti-CD11a mAb clone HI111 (4.8 ± 0.8 ng/ml) and by an anti-CD18 mAb (4.6 ± 1.1 ng/ml) (Fig. 5A). However, anti-CD11a mAbs were differentially able to coimmunoprecipitate bound ESM-1; the blocking anti-CD11a mAb (clone HI111), which is known to inhibit the binding of ICAM-1, coimmunoprecipitated ESM-1, whereas the nonblocking anti-CD11a mAb (clone G43-25B) was inefficient, despite similar MFIs obtained by FACS.
isotype-matched nonblocking G43-25B control, anti-CD11a mAb (6.1 ± 0.5 ng/ml). These results demonstrate a physical association between ESM-1 and LFA-1 and that the binding of ESM-1 may be regulated by the specific anti-CD11a mAb clone HI111.

Real-time interaction between LFA-1 and ESM-1

To better define the interaction between LFA-1 and ESM-1, a real-time observation by Biacore analysis was conducted. The Sensor Chip was filled with detergent lysates of Jurkat cells to capture functional LFA-1 molecules. Specific binding of the heterodimeric form of LFA-1 to the anti-CD11a mAb-coupled Sensor Chip was observed, which is essential to keep LFA-1 functional (Fig. 6A). When ESM-1 was bound to LFA-1, it was allowed to bind to the immobilized LFA-1 (0–250 s), and a slow dissociation phase, in which the ESM-1 solution was replaced with running buffer (250–600 s). The association and dissociation phases were fitted and linearized according to the BIAevaluation software (version 3.1). The $K_d$ calculated from the rate constants, was 18.7 × 10^{-9} M.

**ESM-1 inhibits the binding of soluble ICAM-1 to Jurkat cells**

The fact that ESM-1 interacted with LFA-1 suggests that ESM-1 might interfere on LFA-1-ICAM-1 interactions. To explore this hypothesis, metabolically labeled and affinity-purified 3D-ICAM-1/Fc (soluble ICAM-1) was used. The specific binding of ICAM-1 to Jurkat cells (4652 ± 156 cpm) was strongly inhibited by the blocking anti-CD11a mAb clone HI111 (837 ± 168 cpm), indicating that in our experimental model, almost all the labeled ICAM-1/Fc was bound to LFA-1 (Fig. 7A). When ESM-1 was coincubated with soluble ICAM-1 and the Jurkat cells, we observed an inhibition of specific binding of soluble ICAM-1 of 64% (37°C). Based on a molecular mass...
of 50 kDa, as observed on Western blot, 300 ng/ml ESM-1 is equal to $1.7 \times 10^{-8} \text{ M}$ and fits the $K_d$ value determined by Biacore analysis ($1.87 \times 10^{-8} \text{ M}$). Conversely, the ability of soluble ICAM-1 to inhibit the binding of ESM-1 to Jurkat cells was explored. The preincubation of Jurkat cells with 3D-ICAM-1/Fc decreased the binding of ESM-1 by 65% ($2.9 \pm 0.3 \text{ ng/ml}$) as compared with controls ($7.2 \pm 0.4 \text{ ng/ml}$). However, the pretreatment of 3D-ICAM-1/Fc with a blocking anti-ICAM-1 mAb totally restored the binding of ESM-1 to Jurkat cells ($6.7 \pm 0.6 \text{ ng/ml}$) (Fig. B). It is unlikely that ESM-1 had the capacity to bind to the soluble 3D-ICAM-1/Fc because ESM-1 was not coprecipitated by 3D-ICAM-1/Fc. Thus, these data demonstrate that ESM-1 and ICAM-1 can compete for the binding to LFA-1, and consequently, ESM-1 might modulate the interaction of LFA-1 and ICAM-1.

Discussion

The present work demonstrates that ESM-1, which is mainly secreted by endothelial cells, interacts physically and functionally with the extracellular domain of the LFA-1 integrin on Jurkat cells and plays a role in the regulation of LFA-1-mediated interactions.

ESM-1 is a chondroitin/dermatan sulfate proteoglycan produced by HUVECs. Its secretion is regulated by cytokines, and it circulates into the bloodstream (20). Because of its constitutive and cytokine-regulated expression restricted to endothelial cells, a role for ESM-1 in endothelial cell-leukocyte interactions has been postulated. In an initial search for a cell surface receptor for ESM-1, we observed that human blood mononuclear cells and two human lymphoblastoid cell lines exhibited specific ESM-1-binding activity as demonstrated by FACS analysis. Interestingly, ESM-1 bound to purified blood lymphocytes and to resting T and B resting lymphoblastoid cell lines, Jurkat, and SIB-1 cells, respectively.

To biochemically characterize the binding sites for ESM-1, the model of the Jurkat cell line was used. We found that the binding of ESM-1 to Jurkat cells was mostly dependent on the presence of divalent ions. This divalent ion-dependent binding of ESM-1 was saturable, consistent with a receptor-like structure. Coimmunoprecipitations demonstrated that ESM-1 was solely coimmunoprecipitated by anti-LFA-1 mAbs. The interaction between ESM-1 and LFA-1 was specific because ESM-1 was not recovered with mAbs directed against other T cell surface molecules such as CD3 and CD44, despite their concomitant expression in the same membrane raft clusters (21). The very low expression of CD11a at the surface of the monocytoid cell lines used may explain the absence of binding of ESM-1. Direct interaction between ESM-1 and LFA-1 was then studied using the Biacore biosensor system. Measurement of the rate constants demonstrated a physical interaction between ESM-1 and LFA-1 with a $K_d$ of 18.7 nM, close to that observed for soluble ICAM-1 and LFA-1 of 60 nM (22), highly consistent with a direct interaction between ESM-1 and LFA-1.

The mapping of the ESM-1 binding site within the LFA-1 molecule was also investigated. Among the two CD11a and the CD18 mAbs tested, two of them are known to block LFA-1-ICAM-1 interaction, but none of them was able to inhibit ESM-1 binding. It can be suggested that the ESM-1-binding site is not identical with the sites involved in LFA-1-ICAM-1 interactions (i.e., the I domain) (23). However, the ESM-1-binding capacity of Jurkat cells was shown to be increased by one LFA-1 mAb (HI111 clone) in the presence of divalent ions; this result reveals that the binding site for ESM-1 can be functionally regulated. The fact that significant amino acid sequence homology does exist between ESM-1 and the cysteine-rich repeats of CD18 suggests that ESM-1 may possibly interact with LFA-1 through its polypeptide moiety in or near this functionally important region (24, 25).
One interesting point is that some differences appeared between the binding characteristics of the couples ESM-1 and LFA-1 and ICAM-1 and LFA-1. In contrast to ICAM-1, the binding of ESM-1 to Jurkat cells was higher at 4°C than at 37°C. Detailed analysis of this difference has not been addressed. Another difference with ICAM-1 was an increase in ESM-1 binding induced by PMA. Maximal binding occurred at 5 min and quickly returned to baseline after 15 min of activation. This pattern more closely resembles the kinetics of TCR-stimulated T cell adhesion to ICAM-1, which peaks at 10 min with a complete return to the low adhesiveness state by 30 min., than PMA stimulation of LFA-1/ICAM-1 adhesion, which is maximal at 10 min and remains high for up to 30 min. (26). These results suggest that the ESM-1 binding site is sensitive to the activation status of LFA-1. They also suggest that among the different conformational states during LFA-1 activation, one of the earliest activation steps should include an up-regulation of the ESM-1 binding site.

We have also investigated the consequences of the binding of ESM-1 on LFA-1/ICAM-1 interaction. We have found that ESM-1 significantly reduced the binding of soluble 3D-ICAM-1/Fc to Jurkat cells. Inversely, the soluble 3D-ICAM-1/Fc was shown to reduce the binding of ESM-1 to Jurkat cells. These results indicate that ESM-1 and ICAM-1, although presumably binding to non-identical sites, can alter LFA-1 conformation to block each other’s binding. ESM-1 is a soluble proteoglycan containing one single chain of glycosaminoglycan (GAG). It has been already shown that GAG chains from proteoglycans can bind through specific binding sites that can be activated by Mn2+ ions (27). Yet, such a direct binding of GAG to LFA-1 integrin has not been documented. Moreover, the lysine-rich specific binding site for GAG found in the α1 chain is not present in the LFA-1 primary sequence. However, the GAG chain of ESM-1 is sulfated, and these sulfate ions might be involved through their association to the LFA-1-fixed divalent ions and interfere with ICAM-1 binding.

The LFA-1 molecule contains specific divalent ion binding sites called metal ion-dependent adhesion site motifs in the conserved region of the extracellular domain of the CD18 chain, in the I domain of the CD11a chain (23), and in the EF hand-like domains. They are essential to regulate the fully activated phenotype of the integrin. Many studies indicate that Ca2+2+ down-regulates the activated state of LFA-1 for ICAM-1 (28–31), whereas Mg2+ and Mn2+ favor conformational changes and appearance of ligand-induced binding sites to obtain the optimal fully activated state of LFA-1 (32–33). In our experimental conditions, such a down-regulation by Ca2+ of ESM-1 binding was not observed; all the three ions equally increased the binding of ESM-1 to Jurkat cells. A similar ion-dependent effect was observed for ESM-1 binding to PBMC, indicating that the ESM-1 binding sites to PBMC and to Jurkat cells shared common features. On a theoretical point of view, ICAM-1 binding to LFA-1 is divided into ligand-binding and ion-binding steps. In the first step, ICAM-1 binds with low affinity to the conserved region of CD18 and the I domain of LFA-1, inducing sequential and conformational changes and access of Mg2+ and Mn2+ ions to their binding sites. Then, the second step occurs through ICAM-1 binding to the last two binding sites localized in the β sheets of the β propeller (34), leading to the high affinity interaction. Here, we can propose that ESM-1 binds through its polypeptide moiety to the proximal ectodomain of the α-chain of LFA-1 in front of the cysteine-rich region of the CD18 and then modifies the access to the ion binding sites or ligand-induced binding sites through its single GAG chain.

The proteoglycan ESM-1, which is secreted by endothelial cells, interacts with LFA-1 and may directly influence LFA-1 function. Thus, ESM-1 may be implicated in the regulation of leukocyte extravasation at the inflammatory sites, because of the essential role of the ICAM-1/LFA-1 interactions during firm adhesion of human lymphocytes and monocytes. In addition, ESM-1 might modulate the LFA-1/ICAM-1 costimulatory pathway on T cells and might orientate the Th1/Th2 balance of the immune response, as it has been reported for anti-ICAM-1 and anti-LFA-1 blocking mAbs (35–37). It is of note that ESM-1 circulates in plasma from healthy subjects and is increased in acute and severe inflammation (20), suggesting that ESM-1 may exert its effects in both healthy and pathological contexts. As ESM-1 levels in blood can reach >100 ng/ml in patients with septic shock (our unpublished data), which are concentrations close to those used here in vitro, it can be speculated that ESM-1 may have potent in vivo regulatory activity on ICAM-1- and LFA-1-mediated functions. Thus, ESM-1 may be considered as a novel class of natural endothelial cell-derived molecules able to regulate LFA-1/ICAM-1 interactions and probably LFA-1-mediated functions. It also offers new insights in the context of drug design in anti-inflammatory strategy.

Acknowledgments

We thank Gwenola Kervoaze and Genevieve Marchandise for their precious technical help.

References


The Journal of Immunology 3105

Downloaded from http://www.jimmunol.org/ by guest on July 25, 2017.


